Everett Harris & Co. CA Increases Stake in Henry Schein, Inc. $HSIC

Everett Harris & Co. CA boosted its position in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 4.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 168,218 shares of the company’s stock after purchasing an additional 7,565 shares during the quarter. Everett Harris & Co. CA owned about 0.14% of Henry Schein worth $12,714,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. LPL Financial LLC grew its position in Henry Schein by 11.3% during the 4th quarter. LPL Financial LLC now owns 29,733 shares of the company’s stock valued at $2,247,000 after purchasing an additional 3,008 shares during the last quarter. Franklin Resources Inc. grew its position in Henry Schein by 17.1% during the 4th quarter. Franklin Resources Inc. now owns 57,331 shares of the company’s stock valued at $4,333,000 after purchasing an additional 8,376 shares during the last quarter. HFR Wealth Management LLC grew its position in Henry Schein by 0.6% during the 4th quarter. HFR Wealth Management LLC now owns 116,963 shares of the company’s stock valued at $8,840,000 after purchasing an additional 647 shares during the last quarter. Los Angeles Capital Management LLC purchased a new stake in Henry Schein during the 4th quarter valued at about $37,000. Finally, Havemeyer Place LP purchased a new stake in Henry Schein during the 4th quarter valued at about $642,000. 96.62% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Henry Schein news, Director William K. Daniel acquired 10,000 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were bought at an average price of $69.19 per share, with a total value of $691,900.00. Following the completion of the acquisition, the director owned 20,000 shares in the company, valued at $1,383,800. This represents a 100.00% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Thomas C. Popeck sold 1,355 shares of the firm’s stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $72.79, for a total transaction of $98,630.45. Following the completion of the transaction, the chief executive officer directly owned 86,182 shares in the company, valued at approximately $6,273,187.78. The trade was a 1.55% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 0.89% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on HSIC shares. Morgan Stanley reissued an “underweight” rating and set a $64.00 price objective (up from $61.00) on shares of Henry Schein in a research report on Friday, April 24th. Leerink Partners restated a “market perform” rating on shares of Henry Schein in a research note on Monday, March 9th. JPMorgan Chase & Co. upped their target price on shares of Henry Schein from $78.00 to $92.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Citigroup initiated coverage on shares of Henry Schein in a research note on Wednesday, April 15th. They set a “buy” rating and a $100.00 target price on the stock. Finally, UBS Group restated a “neutral” rating and set a $85.00 target price (down from $87.00) on shares of Henry Schein in a research note on Wednesday, May 6th. Six investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Henry Schein has an average rating of “Hold” and an average price target of $86.83.

Henry Schein Stock Performance

HSIC opened at $78.05 on Tuesday. The company has a current ratio of 1.36, a quick ratio of 0.75 and a debt-to-equity ratio of 0.59. The company has a market cap of $8.89 billion, a price-to-earnings ratio of 23.58, a PEG ratio of 1.49 and a beta of 0.82. The company’s 50 day moving average is $74.79 and its 200 day moving average is $76.01. Henry Schein, Inc. has a 12-month low of $61.94 and a 12-month high of $89.29.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $1.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.20 by $0.12. The company had revenue of $3.37 billion for the quarter, compared to the consensus estimate of $3.34 billion. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The firm’s revenue was up 6.3% compared to the same quarter last year. During the same quarter last year, the firm posted $1.15 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, equities research analysts predict that Henry Schein, Inc. will post 5.32 EPS for the current year.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.